Short Summary
The PTAB instituted an inter partes review of Inari Medical’s 11,554,005 patent covering intravascular embolism treatment devices after finding Imperative Care’s likelihood of success on at least one claim. The decision centers on claim constructions of the “filament” element and obviousness over multiple prior‑art references.
Detailed Summary
In a Decision Granting Institution of Inter Partes Review, the Patent Trial and Appeal Board concluded that Imperative Care, Inc. has shown a reasonable likelihood of prevailing on at least one of the fifteen claims of Inari Medical’s U.S. Patent No. 11,554,005 B2, which claims a vacuum aspiration system with a hemostasis valve. The Board examined four statutory grounds, all under 35 U.S.C. § 103, relying on prior‑art references Garrison, Schaffer, Hartley, and Eller. A key dispute involved the term “filament,” where the petitioner defined it broadly, the patent owner emphasized flexibility, and the Board declined to limit the term for claim 1 while requiring flexibility for claim 10. Consequently, the IPR was instituted on all challenged claims, setting the stage for a full trial on obviousness and claim construction issues.
Practitioner Note
This case demonstrates the evidentiary and procedural standards applied in patent matters before local courts. Understanding the court's reasoning in Imperative Care, Inc. vs Inari Medical, Inc. et al. is valuable context for structuring arguments or assessing risk in similar proceedings.
Related Cases
Cambridge Mobile Telematics, Inc.vsSfara, Inc.
Cambridge Mobile Telematics, Inc. filed a Petition challenging Sfara, Inc.'s patent on vehicle identification technology. The core argument asserts that the challenged claims are obvious over prior art references Fong and Abramson. Petitioner contends that combining sensor signature detection with comparison methods was known in the field.
Kingston Technology Company, Inc., Kingston Technology Corporation, and Kingston Digital, Inc.vsVervain, LLC
The PTAB denied Phison Electronics' post‑grant review petition against Vervain's NAND‑flash storage patent, finding the challenger failed to meet the more‑likely‑than‑not standard for unpatentability.
Amazon.com, Inc. et al.vsDatonics LLC
Amazon and Datonics have settled their IPR dispute over U.S. Patent 10,984,445 and jointly request the Board to terminate the proceeding while keeping the settlement agreement confidential.
Precision Cancer Technologies Inc.vsOncoustics Inc.
Precision Cancer Technologies has petitioned the PTAB to invalidate Oncoustics’ 330 Patent covering ultrasound‑based machine‑learning classification, arguing that the claims are anticipated or obvious over prior art such as Hope‑Simpson, Nair and Azizi.
SAMSUNG ELECTRONICS CO., LTD. et al.vsVasu Holdings, LLC
Samsung seeks Director review of a PTAB decision that denied institution of its IPRs, arguing that the USPTO’s retroactive rescission of the Vidal Memo violated due process and the APA, and that the Board ignored Samsung’s timely Sotera stipulation.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.
Disclaimer: This page contains an automated summary based on publicly available judicial records. The content is generated for informational purposes only and does not constitute legal advice. Always verify details against the original source judgment before relying on this information for any legal purpose. If you believe any information is inaccurate, please contact us.